文献速递心血管胸部PETMRCT

FDG PET与心脏MRI在心脏结节病诊断及免疫抑制治疗监测中的价值

Utility of FDG PET and Cardiac MRI in Diagnosis and Monitoring of Immunosuppressive Treatment in Cardiac Sarcoidosis.
PubMed 文献 · Radiol Cardiothorac Imaging · 2020-08-27

本研究为回顾性观察性研究,纳入31例经证实有心脏外结节病且疑诊心脏结节病的患者,比较FDG PET/CT与心脏MRI在诊断和管理中的贡献。结果显示,17例后续接受治疗的患者在首次检查时可见显著心肌FDG摄取(SUVmax>3.6),治疗后心肌SUVmax从6.5降至4.0(P<.01),心脏代谢体积从42.5降至4.1(P<.001),LVEF从45.8%升至50.9%(P<.031),而晚期钆增强体积无变化;未治疗患者所有参数均无变化。

要点

  • 心肌FDG摄取(SUVmax>3.6)提示活动性炎症,治疗后SUVmax及心脏代谢体积显著下降。
  • 心脏代谢体积可作为评估治疗反应的客观定量指标。
  • 晚期钆增强体积在治疗前后无变化,未治疗患者FDG PET及心脏MRI参数均无变化。

关键影像表现/征象

  • 首次检查时,22例后续接受治疗的患者中有17例显示显著心肌FDG摄取(心肌SUVmax>3.6)。
  • 随访时心肌SUVmax从6.5降至4.0(P<.01),FDG高摄取肺及纵隔淋巴结病变也显著减少。
  • 以阈值SUV定义的心肌体积(心脏代谢体积)均值从42.5降至4.1(P<.001)。
  • 左心室射血分数(LVEF)从45.8%升高至50.9%(P<.031)。
  • 晚期钆增强体积在治疗时无变化;未治疗患者任何FDG PET或心脏MRI参数均无变化。

诊断标准与关键数值

  • 心肌FDG摄取显著定义为心肌SUVmax>3.6(用于首次检查时识别后续治疗患者)。
  • 心脏代谢体积为高于阈值SUV的心肌体积定量指标,治疗后均值从42.5降至4.1(P<.001)。

临床应用与阅片要点

  • 对疑诊心脏结节病患者,可结合FDG PET/CT与心脏MRI评估活动性炎症及治疗反应。
  • 心肌SUVmax>3.6及心脏代谢体积可用于客观定量监测治疗反应。
  • 晚期钆增强体积在治疗后无变化,解读时应结合FDG PET代谢指标。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To compare the contributions of cardiac MRI and PET in the diagnosis and management of cardiac sarcoidosis (CS), with particular reference to quantitative measures.

MATERIALS AND METHODS: This is a retrospective, observational study of 31 patients (mean age, 45.7 years) with proven extracardiac sarcoidosis and possible CS who were investigated with fluorine 18 fluorodeoxyglucose (FDG) PET/CT and cardiac MRI. Patients were treated at physicians' discretion with repeat combined imaging after an interval of 102-770 days (median, 228 days).

RESULTS: Significant myocardial FDG uptake was shown on visit 1 (myocardial maximum standardized uptake value [SUVmax] > 3.6) in 17 of 22 patients who were subsequently treated. Myocardial SUVmax decreased at follow-up (6.5 to 4.0; P < .01) and was matched by significant decreases in FDG-avid lung and mediastinal node disease. A volumetric measure of myocardium above a threshold SUV (cardiac metabolic volume) decreased from a mean of 42.5 to a mean of 4.1 (P < .001). This was associated with significant improvement in the left ventricular ejection fraction (LVEF) (45.8 increasing to 50.9; P < .031). There was no change in volume of late gadolinium enhancement at treatment. Patients who were untreated showed no change in any FDG PET or cardiac MRI parameter.

CONCLUSION: Myocardial FDG uptake in patients suspected of having CS is presumed to represent active inflammation. When treated with corticosteroids, this resolved or regressed at follow-up, with an improvement in LVEF and FDG-avid thoracic disease. Patients who were untreated showed no change in any parameter. Quantification of FDG-avid myocardium using cardiac metabolic volume is proposed as a useful objective measure for assessing response to therapy.© RSNA, 2020See also commentary by Gutberlet in this issue.

来源:Radiol Cardiothorac Imaging,查看原文。版权归原作者所有。

引用

  1. Coulden RA, Sonnex EP, Abele JT, et al. Utility of FDG PET and Cardiac MRI in Diagnosis and Monitoring of Immunosuppressive Treatment in Cardiac Sarcoidosis. Radiol Cardiothorac Imaging. 2020. PMID: 33778595. doi:10.1148/ryct.2020190140

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。